Device for an electrophysiology procedure

Description

The current International Patent Application is a continuation of PCT/IB2020/062261 and PCT/IB2020/055111, both claiming priority to DE102018133630 and entirely embedded herein as reference.

PCT/IB2020/055111 demonstrated for the first time the mechanism of cardiac arrhythmias through the negative differential resistance (NDR), wherein PCT/IB2020/062261 provided for the first time a quantum electrophysiology device and a quantum built-in cardiac implantable cardiac device through the NDR-Measurement (NDR-M).

Further on, the NDR-M can be used to the Qi-Measurement (Qi-M) and to the external Qi (EQ) EQ-Measurement (EQ-M) in the traditional Chinese medicine (TCM).

The aforementioned Patent Applications paved the way into the quantum cardiac electrophysiology, a strategic trend in physiology, pathology and medicine.

Exceeding the prior art, the invention provides in one first embodiment a spontaneously occurring NDR-M-free state, namely the first quantum arrhythmic vacuum (QAV1) of one quantum spin liquid (QSL), wherein the QSL is the quantum spacetime in which one arrhythmia happens to occur in a living being.

Exceeding the prior art, the invention provides in one second embodiment an induced NDR-M-free state, namely the second quantum arrhythmic vacuum (QAV2) of the quantum spin liquid (QSL), wherein the QSL is the quantum spacetime in which one arrhythmia occurs in a living being.

Further on, the invention provides for the first time the QAV-switch between QAV1 and QAV2 through at least one entangled NDR-M. The induction of QAV2 may be regarded as a therapeutic resource by those skilled in the art and does not meet the purpose of the invention.

Exceeding the prior art, the NDR-M may take place remote from the arrhythmic substrate, within the body or remote from it.

Particular structures of the heart may harvest the QSL, such as by the left atrial appendage (LAA) occlusion with QSL, by the atrial septal pouches in-filing with QSL, but not limited to them, wherein QSL is tailored in such a way to resist the immune response, the accidental or not desired blood clotting and viral and/or bacterial colonisation.

Particular structures of the body, as well as underlying tumours may harvest the QSL, wherein QSL is tailored in such a way to resist the accidental or not desired immune response, blood clotting and viral and/or bacterial colonisation.

Although the invention has been illustrated and described in detail by the embodiments previously explained, it is not limited to these embodiments. Other variations may be derived by the skilled person without leaving the scope of the attached claim.

In addition, numerical values previously applied may include the exact values as well as a tolerance interval, unless this is explicitly excluded.

Features shown in the embodiments, in particular in different embodiments, may be combined or substituted without leaving the scope of the invention.